"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) |
||
| Line 50: | Line 50: | ||
<a href="http://http://www.sigmaaldrich.com/" target="_blank"> | <a href="http://http://www.sigmaaldrich.com/" target="_blank"> | ||
<img title="Sigma-Aldrich" style="width: 250px;" src="https://static.igem.org/mediawiki/2009/6/67/SA_Logo.jpg";> | <img title="Sigma-Aldrich" style="width: 250px;" src="https://static.igem.org/mediawiki/2009/6/67/SA_Logo.jpg";> | ||
| + | </a> | ||
| + | <a href="http://www.eurogentec.com/" target="_blank"> | ||
| + | <img title="Eurogentec" style="width: 250px;" src="https://static.igem.org/mediawiki/2009/a/a2/Logo-EGT-fond-blanc.jpg";> | ||
</a> | </a> | ||
</div> | </div> | ||
</center> | </center> | ||
</html> | </html> | ||
| - | |||
| - | |||
Revision as of 13:39, 17 September 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
Contents |
UMR CNRS 8121 from the Gustave Roussy Institute
- Dr. Lluis M. Mir
- Dr. Karim Benihoud
INSERM U872
- Dr. Srinivas Kaveri
AnyGenes
- Dr. Benyoussef Naimi
National Reference Center for Mycobacteria and the Resistance of Mycobacteria to Antituberculosis from CHU Pitié-Salpêtrière
- Dr. Nicolas Veziris
Our Sponsors
